You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Professional Issues Articles
Popular Professional Issues Articles
Highly Recommended Professional Issues Articles
Send a link to this page to your friends and colleagues.
A recent study compared the effect of adding exenatide (Byetta) or insulin glargine (Lantus) to type 2 patients’ treatment regimens. The type 2s previously had been taking metformin and a sulfonylurea with little success.
According to the researchers, patients taking Byetta at dosages of 10 micrograms twice daily achieved reductions in glucose measures similar to those of patients taking Lantus.
“[Byetta] reduced postprandial glucose excursions more than insulin glargine, while insulin glargine reduced fasting glucose concentrations more than [Byetta],” write the researchers.
Byetta patients also lost an average of 5 pounds, while patients on Lantus gained an average of 4 pounds. Rates of symptomatic hypoglycemia were similar between treatment groups.
The most common adverse event for Byetta users was nausea, which was experienced by 57 percent of the participants. Six percent of Byetta participants discontinued its use due to nausea.
—Annals of Internal Medicine, October 18, 2005
Apr 1, 2006
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.